Navigation Links
New Research: Nationwide Report Shows Prescribed Drugs Not Detected in More Than One-Third of Pain Patient Samples

BALTIMORE, June 20, 2013 /PRNewswire/ -- A new report issued today by Ameritox, the nation's leader in pain medication monitoring, revealed that more than one-third (35.9 percent) of samples collected from patients prescribed opioid medications for chronic pain management last year did not contain their prescribed drug, an increase from the 31 percent found in similar research released in October 2010.

In both the 2010 and 2012 surveys, Ameritox analyzed samples from more than half a million patients collected over a twelve-month period. The samples used in the 2012 report came from approximately 527,000 individual patients from all 50 states.

"It appears that the epidemic of prescription pain medication abuse is worsening," said Ameritox Chief Executive Scott Walton. "Medication monitoring helps doctors discern medication use, but monitoring alone won't solve the problem. The front line in the battle against pain medication abuse and addiction is at the clinical level, and we will be vigilant in equipping doctors with the best possible tools to face this challenge head on."

Kathryn Bronstein, Vice President of Medical Affairs at Ameritox, said that the data underscores the importance of medication monitoring. "There is no doubt that pain medication is critical to the care millions of individuals receive across the country. For many people living with chronic pain, these medicines are the only option for relief of their symptoms. But they must be used correctly to be used safely."

This most recent survey showed that the District of Columbia (47.8 percent), Michigan (45.8 percent), Georgia (45.8 percent), South Carolina (45.7 percent) and Missouri (44.1 percent) had the highest percentage of tests that failed to show the prescribed medication. Minnesota (3 percent), Vermont (14.9 percent) and Maine (16.5 percent) reported the lowest percentages. The complete findings from states with more than 1,000 tests are available at

In addition to monitoring use of prescribed medications, Ameritox also screens for the presence of other drugs. Nearly one-third (32.3 percent) of the tests detected substances not prescribed by the attending physician, an increase from the 29 percent found in 2010. In both surveys, 11 percent of all samples contained an illicit drug, primarily marijuana. A significant number of tests also found cocaine. Ameritox's research has shown that users of illicit drugs are more likely than non-users to be potentially non-adherent to their prescription drug regimen.

"Consistent, appropriate monitoring for the presence of prescribed, non-prescribed and illicit drugs  not only enables doctors to provide better care, but can also help reduce misuse, abuse and diversion,"  Walton said. "We hope that medication monitoring results can spark a conversation between a doctor and patient.  We believe these conversations will lead to the improved health and wellbeing of the patient."

About Ameritox
Ameritox is the nation's leader in Pain Medication Monitoring SolutionsSM, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provide physicians with the information and support they need to enhance and optimize the care of chronic pain patients. Monitoring through prescription drug testing can help physicians make more informed clinical decisions while also helping to reduce the possible risk of misuse, abuse or diversion of powerful medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at, on Twitter @Ameritox, on Facebook at, and on YouTube at

© 2013 Ameritox Ltd. All rights reserved. Ameritox, Ameritox-Medication Monitoring Solutions, Rx Guardian, Rx Guardian INSIGHT and Rx Guardian CD are trademarks of Ameritox. Other trademarks are the property of their owners.

SOURCE Ameritox
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Devices Research: Country Reports on Market Profile, Competitive Environment and more at
2. Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets
3. Presenting Sponsor Mylan Specialty L.P. Calls on Communities Nationwide to Join The Food Allergy Research & Education (FARE) Walk for Food Allergy
4. Green Valley Drugs Announces Voluntary Nationwide Recall Of All Lots Of All Sterile Products Compounded, Repackaged, And Distributed By Green Valley Drugs Due To Quality Control Concerns
5. CVS Caremark Charitable Trust Supports Non-profits Nationwide with $2.6 Million in Funding
6. Quest Diagnostics to Provide Nationwide Access to Nateras New Non-Invasive Prenatal Test
7. Swisse Wellness, Australias #1 Multivitamin Brand, Arrives at Walgreens Stores Nationwide
8. MDH Radiology Selects Sectra for Nationwide Telemammography Solution
9. Qualitest Issues Voluntary, Nationwide Recall of 101 Lots of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets
10. Ranbaxy Issues Voluntary Nationwide Recall of 41 lots of Atorvastatin Calcium Tablets 10 mg, 20 mg and 40 mg Due to Potential Presence of Foreign Substance
11. Zi Xiu Tang Success, LLC Issues Voluntary Nationwide Recall of Classic Zi Xiu Tang Bee Pollen Capsules and Ultimate Formula Capsules due to Undeclared Sibutramine
Post Your Comments:
(Date:11/27/2015)... 2015 Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... Une nouvelle approche consistant à combiner l,immunothérapie au ...    Clinical Cancer Research . ...
(Date:11/27/2015)... NEW YORK , November 27, 2015 ... health system is set to go online. The potential ... and processes is vast and far from fully exploited ... access to patient health records, either via mobile tablet ... ) --> ) ...
(Date:11/27/2015)... Niederlande, November 27, 2015 ... bei fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... ... analog distortion effect tool designed specially for Final Cut Pro X. FCPX ... looks with the easy-to-use modification controls. Destoying and creating chaotic distortion is now ...
(Date:11/29/2015)... ... ... Effective immediately, every single IguanaMed scrub style will be available at Target ... a “Buy One Scrub Set, Get the 2nd Scrub Set 50% Off” for a ... discounted price. , IguanaMed’s mission is to outfit every healer around the ...
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated corporate housing ... December, 2015, featured apartment community: Epic. In showcasing this featured apartment community in San ... Bay Area rental market to efficiently find housing suitable to their needs by showcasing ...
(Date:11/28/2015)... San Diego, California (PRWEB) , ... November 28, ... ... cloud-based medical image exchange technology and teleradiology services, has added Chris Hafey and ... prepares to exhibit at the Radiological Society of North America (RSNA) 2015 Annual ...
(Date:11/28/2015)... ... ... Safe storage for contraceptive devices may not always be easy to find. However, ... other from Bradley Beach, New Jersey, there is an easy solution to the problem. ... NuvaRings more often than necessary. As such, it affords peace of mind and eliminates ...
Breaking Medicine News(10 mins):